Aerami presents positive data for inhaled pulmonary hypertension treatment

Aerami Therapeutics today announced positive data supporting its inhaled imatinib for treating pulmonary hypertension (PH).

Studies of AER-901 support progression into a Phase 2 clinical trial. Data backed Aerami’s treatment for both PH associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

AER-901 is a drug-device combination. Aerami designed it to deliver potentially reverse-remodeling imatinib therapy deeply and efficiently throughout diseased tissue of the lung. Delivery takes place through a high-performance, handheld, smart nebulizer. It controls flow rates and provides patients with real-time feedback to optimize lung deposition.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Inhaled drug delivery tech company Aerami to go public through SPAC merger

Aerami Therapeutics announced today that it entered into a merger agreement with FoxWayne Enterprises Acquisition Corp. (NSDQ:FOXWU).

Through the definitive business combination agreement with the special purpose acquisition company (SPAC), Aerami, a developer of inhaled therapies for treating respiratory and chronic diseases, will be listed on the Nasdaq market as “Aerami Therapeutics Holdings, Inc.”

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0